| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/19/1993 | WO1993015608A1 Prevention of retinal injury and degeneration by specific factors |
| 08/19/1993 | WO1993015109A3 Parathyroid hormone fragments, their preparation and medicaments containing the same |
| 08/19/1993 | WO1993013741A3 Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors |
| 08/19/1993 | CA2131550A1 Interferon gene therapy for the treatment of vascular disorders |
| 08/19/1993 | CA2130106A1 Amadori reaction compounds and products, process for their manufacture, and their use |
| 08/19/1993 | CA2129754A1 Compositions and processes for the sustained release of drugs |
| 08/19/1993 | CA2129533A1 Improved alpha interferon composition and method for its production from human peripheral blood leukocytes |
| 08/19/1993 | CA2129445A1 Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5 |
| 08/19/1993 | CA2129370A1 Protease-resistant thrombomodulin analogs |
| 08/19/1993 | CA2129351A1 Use of synthetic peptides to induce tolerance to pathogenic t and b cell epitopes of autoantigens |
| 08/19/1993 | CA2129033A1 Radiolabelled peptide compounds |
| 08/19/1993 | CA2129032A1 Phenylalanine analogs of bombesin |
| 08/19/1993 | CA2107343A1 Novel hexapeptidic derivatives, process for the preparation thereof and use thereof as medicaments |
| 08/19/1993 | CA2106854A1 Extract of bacterial macromolecules, a process for its preparation and a pharmaceutical composition containing the same |
| 08/19/1993 | CA2089541A1 Selective removal of n-terminal extensions from folded insulin precursors using dipeptidyl-aminopeptidase-1 |
| 08/19/1993 | CA2086910A1 Food supplement preparation process using microseptor-type mesenchymal substances |
| 08/18/1993 | EP0556124A1 New peptide derivatives, process to prepare them and their use as medicaments |
| 08/18/1993 | EP0556111A1 Hybrid protein complexes, their process of preparation, and their applications as an agent in diagnostic and in the therapeutic field or as a reagent relevant in medical approaches |
| 08/18/1993 | EP0556096A1 Composition for stabilizing bloodplasma during pasteurization and pasteurized plasma solution for therapeutic use |
| 08/18/1993 | EP0556083A1 Process for the production of biologically active substances from milk and related raw materials |
| 08/18/1993 | EP0556051A1 Use of bilobalide and derivatives thereof for treating an infection in an individual and pharmaceutical compositions adapted for such use |
| 08/18/1993 | EP0555898A2 Medicaments for non-topical use |
| 08/18/1993 | EP0555880A2 The CD40CR receptor and ligands therefor |
| 08/18/1993 | EP0555785A1 Smooth muscle mitogen and DNA coding therefor |
| 08/18/1993 | EP0555537A2 Endothelin antagonistic substance |
| 08/18/1993 | EP0555479A1 Epoxysuccinamic acid derivative |
| 08/18/1993 | EP0555425A1 Antibodies to streptolysin o derivatives and variants |
| 08/18/1993 | EP0555413A1 Methods and compositions for suppressing allograft rejection in mammals |
| 08/18/1993 | EP0555397A1 Polypeptide with kd hmfg differentiation antigen binding specificity |
| 08/18/1993 | EP0555363A1 Identification of a suppressor of atherogenic apolipoprotein |
| 08/18/1993 | EP0555328A1 Platelet aggregation inhibitors |
| 08/18/1993 | EP0555286A1 Cell growth inhibitors |
| 08/18/1993 | EP0555231A1 REGULATION OF NEOPLASTIC CELL PROLIFERATION VIA A NOVEL 5HT1a RECEPTOR |
| 08/18/1993 | EP0555205A1 Dna encoding a growth factor specific for epithelial cells |
| 08/18/1993 | EP0555201A1 Recombinant dna coding for bacillus thuringiensis endotoxin |
| 08/18/1993 | EP0493485A4 Erection-inducing methods and compositions |
| 08/18/1993 | EP0425482B1 Human insulin analogs and preparations containing them |
| 08/18/1993 | EP0380484B1 Use of a lysozyme dimer and/or a ribonuclease dimer for th emanufacture of an antiviral or antibiotic drug |
| 08/18/1993 | EP0262178B1 Amino acid chelated compositions for delivery to specific biological tissue sites |
| 08/18/1993 | CN1075253A Compositions and processes for the sustained release of drugs |
| 08/18/1993 | CN1021790C Improvements in or relating to a method for increasing the feed intake of an animal |
| 08/18/1993 | CA2089530A1 Cosmetic and/or pharmaceutical compositions and methods for their use |
| 08/17/1993 | US5237054 Stabilized aqueous composition containing antibodies |
| 08/17/1993 | US5237053 Vaccines containing flagellar antigens |
| 08/17/1993 | US5236933 Use of a combination of angiotensin-converting enzyme inhibitor and calcium antagonist for the treatment of proteinuria |
| 08/17/1993 | US5236927 Reduced toxicity; side effect reduction |
| 08/17/1993 | US5236905 In vitro method of inhibition of HIV using transforming growth factor-.beta. |
| 08/17/1993 | US5236904 Erection-inducing methods and compositions |
| 08/17/1993 | US5236903 Polypeptide comprising repeated cell-adhesive core sequences |
| 08/17/1993 | US5236901 Treatment for irritable bowel syndrome |
| 08/17/1993 | US5236900 Treating Candida infections |
| 08/17/1993 | US5236899 6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance |
| 08/17/1993 | US5236898 Hirudin derivative |
| 08/17/1993 | US5236844 Dna sequences |
| 08/17/1993 | US5236829 Method of producing monokine induced by gamma interferon |
| 08/17/1993 | US5236707 Primary alkylamine; storage stability |
| 08/17/1993 | US5236706 Pharmaceutical preparation for the maturation of prothymocytes |
| 08/17/1993 | US5236705 Fibrinolysis |
| 08/17/1993 | CA1321349C Therapeutic combination of free-radical scavenger or metabolic inhibitor and biologically active protein |
| 08/17/1993 | CA1321348C Treatment of certain leukemias with a combination of gamma interferon and alpha interferon |
| 08/17/1993 | CA1321347C Human leukocyte interferon composition and skin treatment |
| 08/16/1993 | EP0652951A4 Gdf-1. |
| 08/15/1993 | WO1993015753A1 Remedy for airway diseases |
| 08/15/1993 | CA2108277A1 Preparation for the therapy of respiratory tract diseases |
| 08/13/1993 | WO1993015759A1 Autoantibody assay and usage in the control of human disease |
| 08/13/1993 | CA2129895A1 Autoantibody assay and usage in the control of human disease |
| 08/13/1993 | CA2089342A1 Peptidic derivatives, process for the preparation thereof and application as drugs of said novel derivatives |
| 08/12/1993 | DE4204694A1 Verfahren zur gewinnung von hochreinem, virusinaktiviertem faktor viii mittels anionenaustauscher-chromatographie Process for the recovery of high purity virus-inactivated factor viii by anion exchange chromatography |
| 08/12/1993 | DE4203965A1 Antidot fuer hirudin und synthetische thrombininhibitoren Antidote for hirudin and synthetic thrombin inhibitors |
| 08/12/1993 | CA2089247A1 Small peptide and pseudopeptide amides inhibiting the proliferation of small-cell and epithelial-cell lung cancer cells |
| 08/12/1993 | CA2089139A1 Complex hybrid proteins, method for preparing them, their applications as diagnostic agent, as agent intended for therapeutic use |
| 08/11/1993 | EP0555135A1 Process for preparing highly purified fibrinogen |
| 08/11/1993 | EP0555087A1 Peritoneal dialysis solutions containing at least one dipeptide |
| 08/11/1993 | EP0554887A1 The use of mammalian liver extract for the manufacture of a medicament to treat presenile or senile dementia |
| 08/11/1993 | EP0554670A2 Specific antibodies against activated platelets, their production and applications in diagnostics and therapeutics |
| 08/11/1993 | EP0554634A1 Stabilized pharmaceutical composition comprising non-glycosylated, reduced, recombinant human IL-2 and process to prepare it |
| 08/11/1993 | EP0554570A2 Stable fibrinogen solution |
| 08/11/1993 | EP0554446A1 Monoclonal antibodies useful in therapy of HIV-1 infection |
| 08/11/1993 | EP0554441A1 Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy |
| 08/11/1993 | EP0554401A1 Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120 |
| 08/11/1993 | EP0554385A1 Cloning and expression of biologically active alpha-n-acetylgalactosaminidase |
| 08/11/1993 | EP0554383A1 Blood coagulation protein antagonists and uses therefor |
| 08/11/1993 | EP0554376A1 Dna construct for providing rna therapy |
| 08/11/1993 | EP0554374A1 Production and use of tracheal antimicrobial peptides |
| 08/11/1993 | EP0554364A1 Lipid a composition as immunogenic agents to prevent or treat gram-negative bacterial infections |
| 08/11/1993 | EP0554356A1 A monoclonal antibody |
| 08/11/1993 | EP0554352A1 A method for transplanting cells into the brain and therapeutic uses therefor |
| 08/11/1993 | EP0554344A1 Pharmaceutical composition for the treatment or prevention of a malignant tumor |
| 08/11/1993 | EP0507870A4 Polyhemoglobin stabilized by purine derivatives and glutathione |
| 08/11/1993 | EP0434749B1 Pharmaceutical compositions for eliciting an immunostimulant effect |
| 08/11/1993 | EP0393140B1 Topical wound-healing preparations comprising interleukin-1 proteins |
| 08/11/1993 | EP0307402B1 Production of m-csf |
| 08/11/1993 | EP0205555B1 Serine protease inhibitors and methods for isolation of same |
| 08/11/1993 | CN1075148A Amplification gene of megakaryocyte |
| 08/10/1993 | US5235049 Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1 |
| 08/10/1993 | US5235043 Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins |
| 08/10/1993 | US5235042 Purified, angiogenic and releasable from heparin, with which it complexes, by salt elution; cationic, culture product from hepatoma or chondrosarcoma cells |
| 08/10/1993 | US5235038 Deletion and substitution analogues of melittin peptide |
| 08/10/1993 | US5235036 Crf analogs |
| 08/10/1993 | US5234957 Compositions and methods for topical administration of pharmaceutically active agents |